Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO prognostic scoring system: Validation by the Gruppo Romano Mielodisplasie Italian regional database

Journal of Clinical Oncology

Volumn 31, Issue 21, 2013, Pages 2671-2677

  Voso, Maria Teresa ^a   Fenu, Susanna ^b   Latagliata, Roberto ^c   Buccisano, Francesco ^d   Piciocchi, Alfonso ^c   Aloe Spiriti, Maria Antonietta ^e   Breccia, Massimo ^b   Criscuolo, Marianna ^a   Andriani, Alessandro ^f   Mancini, Stefano ^g   Niscola, Pasquale ^h   Naso, Virginia ^e   Nobile, Carolina ⁱ   Piccioni, Anna Lina ^j   D’Andrea, Mariella ^k   D’Addosio, Ada ^l   Leone, Giuseppe ^a   Venditti, Adriano ^d  

^a CATHOLIC UNIVERSITY   (Italy)

^b San Giovanni Hospital Addolorata   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^g SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^h S EUGENIO HOSPITAL   (Italy)

ⁱ UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^j SANDRO PERTINI HOSPITAL   (Italy)

^k REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^l FATEBENEFRATELLI HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; AZACITIDINE; CYTOTOXIC AGENT; FERRITIN; LACTATE DEHYDROGENASE; LENALIDOMIDE; VITAMIN;

ADULT; AGED; ARTICLE; BONE MARROW; CONTROLLED STUDY; CYTOGENETICS; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKEMIA FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL PREDICTION; WHO PROGNOSTIC SCORING SYSTEM; BLOOD; DISEASE COURSE; INTERNATIONAL COOPERATION; METHODOLOGY; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 84890467356     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.0764     Document Type: Article

References (22)

1. Garcia-Manero G: Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 87:692-701, 2012
2. Raza A, Galili N: The genetic basis of pheno-typic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer 12:849-859, 2012
3. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997
4. Malcovati L, Porta MG, Pascutto C, et al: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 23:7594-7603, 2005
5. Malcovati L, Germing U, Kuendgen A, et al: Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503-3510, 2007
6. Kantarjian H, O’Brien S, Ravandi F, et al: Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113:1351-1361, 2008
7. Della Porta MG, Malcovati L, Strupp C, et al: Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 96:441-449, 2011
8. Greenberg PL, Tuechler H, Schanz J, et al: Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454-2465, 2012
9. Schanz J, Tüchler H, Solé F, et al: New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oli-goblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30:820-829, 2012
10. Bennett JM, Catovsky D, Daniel MT, et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189-199, 1982
11. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia, rationale and important changes. Blood 114:937-951, 2009
12. Malcovati L, Della Porta MG, Strupp C, et al: Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 96: 1433-1440, 2011
13. McCullagh P, Nelder JA: Generalized Linear Models. London, United Kingdom, Chapman & Hall, 1989, pp 476-478
14. Leone G, Fianchi L, Voso MT: Therapy-related myeloid neoplasms. Curr Opin Oncol 23:672-680, 2011
15. Bowen DT, Fenaux P, Hellstrom-Lindberg E, et al: Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and practical application. J Clin Oncol 26:1180, 2008
16. Kao JM, McMillan A, Greenberg PL: International MDS Risk Analysis Workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 83:765-770, 2008
17. Cazzola M, Della Porta MG, Malcovati L: Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 166-175, 2008
18. Alessandrino EP, Della Porta MG, Bacigalupo A, et al: Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: A GITMO study. Haematologica 95:476-484, 2010
19. Germing U, Hildebrandt B, Pfeilstöcker M, et al: Refinement of the International Prognostic Scoring System (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 19:2223-2231, 2005
20. Wimazal F, Sperr WR, Kundi M, et al: Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. Ann Oncol 19:970-976, 2008
21. Park S, Grabar S, Kelaidi C, et al: Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience. Blood 111:574-582, 2008
22. Fenaux P, Giagounidis A, Selleslag D, et al: A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood 118:3765-3776, 2011